RT Journal Article
T1 Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial.
A1 Becerra-Tomás, Nerea
A1 Ruiz-Canela, Miguel
A1 Hernández-Alonso, Pablo
A1 Bulló, Mònica
A1 Li, Jun
A1 Guasch-Ferré, Marta
A1 Toledo, Estefanía
A1 Clish, Clary B
A1 Estruch, Ramon
A1 Ros, Emilio
A1 Fitó, Montserrat
A1 Lee, Chih-Hao
A1 Pierce, Kerry
A1 Arós, Fernando
A1 Serra-Majem, Lluís
A1 Liang, Liming
A1 Razquin, Cristina
A1 Gómez-Gracia, Enrique
A1 Martínez-González, Miguel A
A1 Hu, Frank B
A1 Corella, Dolores
A1 Salas-Salvadó, Jordi
K1 PREDIMED study
K1 atrial fibrillation
K1 glycolysis
K1 heart failure
AB The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case-control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR for 1 SD increase: 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies.
SN 2218-1989
YR 2021
FD 2021-05-11
LK https://hdl.handle.net/10668/26601
UL https://hdl.handle.net/10668/26601
LA en
DS RISalud
RD Apr 8, 2025